Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Psychiatry
Erschienen in: Current Treatment Options in Psychiatry 4/2015

01.12.2015 | Suicide (MS Goodman, Section Editor)

“Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?”

verfasst von: Laili Soleimani, MD, Alison Welch, MD, James W. Murrough, MD

Erschienen in: Current Treatment Options in Psychiatry | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Excerpt

Suicide is defined as an act of violence toward oneself with the intention to die. Suicide completion is a prominent cause of worldwide mortality, and its prevention poses a major challenge to the psychiatric and world health communities. The Centers for Disease Control and Prevention (CDC) reported that as of 2013, suicide was the tenth major cause of death—totaling 41,149 deaths in the USA (CDC) [1]. Despite a growing armamentarium of psychiatric medications to treat mood disorders, effective pharmacologic interventions for suicidality continue to elude us. Statistics demonstrate no meaningful decrease in the rate of suicide [2, 3]. In fact, within the USA, there has been an alarming 28.4 % increase in the age-adjusted suicide rates (from 13.7 to 17.6 per 100,000) for adults aged 35–64 years between 1999 and 2010 (CDC [4]), as well as a 2.4 % increase in the age-adjusted death rate due to suicide in 2012 compared to 2011 [5]. …
Literatur
1.
2.
3.
4.
5.
6.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC. 2013.
7.
Brown GK et al. Risk factors for suicide in psychiatric outpatients: a 20-year prospective study. J Consult Clin Psychol. 2000;68(3):371–7.CrossRefPubMed
8.
Moller HJ. Evidence for beneficial effects of antidepressants on suicidality in depressive patients: a systematic review. Eur Arch Psychiatry Clin Neurosci. 2006;256(6):329–43.CrossRefPubMed
9.
Mann JJ et al. Suicide prevention strategies: a systematic review. JAMA. 2005;294(16):2064–74.CrossRefPubMed
10.
Cipriani A et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.CrossRefPubMed
11.
Ahrens B, Muller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect? Pharmacopsychiatry. 2001;34(4):132–6.CrossRefPubMed
12.
Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry. 2004;12(1):14–41.PubMed
13.
Kovacsics CE, Gottesman II, Gould TD. Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol. 2009;49:175–98.CrossRefPubMed
14.
Montagnon F, Said S, Lepine JP. Lithium: poisonings and suicide prevention. Eur Psychiatry. 2002;17(2):92–5.CrossRefPubMed
15.
Meltzer HY et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91.CrossRefPubMed
16.
Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012;6(3):134–44.CrossRefPubMed
17.
Husain MM et al. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a consortium for research in ECT (CORE) report. J Clin Psychiatry. 2004;65(4):485–91.CrossRefPubMed
18.
American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder, Third Edition, 2010.
19.
20.
Fink M, Kellner CH, McCall WV. The role of ECT in suicide prevention. J ECT. 2014;30(1):5–9.CrossRefPubMed
21.
Berman RM et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.CrossRefPubMed
22.•
Murrough JW et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–42. This RCT is currently the largest study comparing efficacy and safety of ketamine to a control condition in patients with treatment resistant major depression.PubMedCentralCrossRefPubMed
23.
Mathew SJ et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13(1):71–82.CrossRefPubMed
24.
Zarate Jr CA et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–64.CrossRefPubMed
25.
Zarate Jr CA et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939–46.PubMedCentralCrossRefPubMed
26.
Diazgranados N et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802.PubMedCentralCrossRefPubMed
27.
28.
Price RB et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522–6.PubMedCentralCrossRefPubMed
29.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.CrossRefPubMed
30.
aan het Rot M et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–45.CrossRef
31.
DiazGranados N et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605–11.PubMedCentralCrossRefPubMed
32.
Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol. 1979;47(2):343–52.CrossRefPubMed
33.
Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7:151–69.CrossRefPubMed
34.
35.
Price RB et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31(4):335–43.PubMedCentralCrossRefPubMed
36.
Beck AT, Steer RA, Ranieri WF. Scale for suicide ideation: psychometric properties of a self-report version. J Clin Psychol. 1988;44(4):499–505.CrossRefPubMed
37.
Rush AJ et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–83.CrossRefPubMed
38.
Rasmussen KG et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013;27(5):444–50.CrossRefPubMed
39.
Conrad AK et al. A psychometric investigation of the suicide status form II with a psychiatric inpatient sample. Suicide Life Threat Behav. 2009;39(3):307–20.CrossRefPubMed
40.
Diamond PR et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28(6):536–44.CrossRefPubMed
41.
Ballard ED et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161–6.CrossRefPubMed
42.
Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14(8):1127–31.CrossRefPubMed
43.•
Murrough JW et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med, 2015: p. 1–10. This study is the first RCT to prospectively assess the efficacy and tolerability of ketamine on SI in patients who present for the treatment of SI across a spectrum of psychiatric disorders
44.
Greenwald AG, McGhee DE, Schwartz JL. Measuring individual differences in implicit cognition: the implicit association test. J Pers Soc Psychol. 1998;74(6):1464–80.CrossRefPubMed
45.
Nock MK et al. Measuring the suicidal mind: implicit cognition predicts suicidal behavior. Psychol Sci. 2010;21(4):511–7.CrossRefPubMed
46.
47.
De Gioannis A, De Leo D. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression. Aust N Z J Psychiatry. 2014;48(7):686.CrossRefPubMed
48.
Zigman D, Blier P. Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report. J Clin Psychopharmacol. 2013;33(2):270–2.CrossRefPubMed
49.•
Oquendo MA et al. Toward a biosignature for suicide. Am J Psychiatry, 2014. This recent review provides a cogent review of the current state of the field concerning the neurobiology of suicide
50.
51.
Sequeira A et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One. 2009;4(8), e6585.PubMedCentralCrossRefPubMed
52.
Choudary PV et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A. 2005;102(43):15653–8.PubMedCentralCrossRefPubMed
53.
Gray AL et al. Sex differences in glutamate receptor gene expression in major depression and suicide. Mol Psychiatry. 2015;20(9):1139.CrossRefPubMed
54.
55.
Lepack AE et al. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol, 2015. 18(1).
56.
Steiner J et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42(2):151–7.CrossRefPubMed
57.
Lindqvist D et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66(3):287–92.CrossRefPubMed
58.
Oxenkrug GF. Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci. 2010;47(1):56–63.PubMedCentralPubMed
59.
60.
Sublette ME et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun. 2011;25(6):1272–8.PubMedCentralCrossRefPubMed
Metadaten
Titel
“Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?”
verfasst von
Laili Soleimani, MD
Alison Welch, MD
James W. Murrough, MD
Publikationsdatum
01.12.2015
Verlag
Springer International Publishing
Erschienen in
Current Treatment Options in Psychiatry / Ausgabe 4/2015
Elektronische ISSN: 2196-3061
DOI
https://doi.org/10.1007/s40501-015-0065-2

Weitere Artikel der Ausgabe 4/2015

Current Treatment Options in Psychiatry 4/2015 Zur Ausgabe

Eating and Other Impulse Control Disorders (J Grant, Section Editor)

Eating Disorders and Their Relationship to Impulsivity

Anxiety, Obsessive Compulsive and Related Disorders (B Brennan and D Dougherty, Section Editors)

Review of Psychopharmacological Approaches for Trichotillomania and Other Body-Focused Behaviors

Suicide (MS Goodman, Section Editor)

Inpatient Cognitive Behavior Therapy Approaches for Suicide Prevention

Suicide (MS Goodman, Section Editor)

Mobile Health Technologies for Suicide Prevention: Feature Review and Recommendations for Use in Clinical Care

Suicide (MS Goodman, Section Editor)

Psychological Approaches to Suicide Treatment and Prevention

INVITED COMMENTARY ON DEPRESSION

A Review of Brain Stimulation Treatments for Late-Life Depression

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise